Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from CFA

ALQGC: New Capital and New Investors Added

By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT

Benzinga

Injured climber winched to safety after Grampians plunge

An injured climber has been winched to safety after falling in the Grampians National Park in Victoria's west last night.

ABC News

AMTI: AMTI is Underappreciated

By Brad Sorensen, CFA NASDAQ:AMTI READ THE FULL AMTI RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

WKSP: April Update

By Thomas Kerr, CFA NASDAQ:WKSP READ THE FULL WKSP RESEARCH REPORT

Benzinga

ENSC: Ensysce Releases Encouraging Financials

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT

Benzinga

TENX: 2021 Financial and Operational Review

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

Benzinga

MITO: Stealth BioTherapeutics' Treatments Gain Momentum

By Brad Sorensen, CFA NASDAQ:MITO READ THE FULL MITO RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

LGVN: LGVN Publishes Positive Alzheimer's Results

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga

UK Withdraws Its Judges From Hong Kong’s Top Court

Britain said keeping its judges in Hong Kong’s Court of Final Appeal would “legitimize oppression” under a controversial security law in the former colony.

The News Lens

EMMA: Emmaus Sickle Cell Treatment Expands Reach

By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT

Benzinga

COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT

Benzinga

IONGF: ION Energy is exploring & advancing two prospective lithium brine projects in Mongolia: the Baavhai Uul Project and the Urgakh Naran Project.

By Steven Ralston, CFA OTCQB:IONGF | TSXV:ION READ THE FULL IONGF RESEARCH REPORT

Benzinga

BIOX: Bioceres Crop Solutions to Merge with Marrone Bio Innovations in order to acquire a solid bio-crop protection product portfolio, additional bio-R&D capabilities and other

By Steven Ralston, CFA NASDAQ:BIOX READ THE FULL BIOX RESEARCH REPORT

Benzinga

BBLG: Bone Biologics Inks Important Supply Agreement

By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BLRX: 2021 Results

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

Benzinga

RVPH: 2021 Results

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

Benzinga

TLSA: KOL Discussion and SPMS 6-Month Results

By John Vandermosten, CFA NASDAQ:TLSA Introduction

Benzinga

ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

LGVN: Longeveron Continues to Make Progress

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga

CANG: December Quarter Results Met Expectations, but Soft Revenue Guidance for March Quarter Should Mark a Quarterly Trough for 2022

By T. Moore, CFA NYSE:CANG READ THE FULL CANG RESEARCH REPORT

Benzinga

LPCN: 2021 Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga

WKSP: Worksport updates investors and stakeholders with multiple press releases

By Thomas Kerr, CFA NASDAQ:WKSP READ THE FULL WKSP RESEARCH REPORT

Benzinga

DRIO: Future Brightens with $40M Raise & Sanofi Deal

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

Benzinga

NOVN: A Banner Year for Novan - 2021 Results

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

Benzinga

COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.